The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / European Commission Approves Subcutaneous Belimumab for SLE; FDA Safety Alert for Febuxostat

European Commission Approves Subcutaneous Belimumab for SLE; FDA Safety Alert for Febuxostat

November 29, 2017 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

In Europe, a subcutaneous formulation of belimumab has been approved to help treat patients with active autoantibody-positive systemic lupus erythematosus (SLE). Meanwhile, the U.S. Food and Drug Administration (FDA) has issued a safety alert for febuxostat, after a safety trial showed an increased risk of heart-related death.

You Might Also Like
  • FDA Issues Boxed Warning for Febuxostat & Approves Colchicine for Gout Flare
  • Subcutaneous Belimumab Improves Systemic Lupus Srythematosus Outcomes
  • Ixekizumab Promising for Non-Radiographic Axial SpA; Plus FDA Approves Belimumab for Pediatric Lupus
Also By This Author
  • Atacicept, Mavrilimumab Drug Updates, Trials, Safety Data

European Commission Approves Subcutaneous Belimumab
A new subcutaneous formulation of belimumab (Benlysta) has been approved by the European Commission.1 The treatment’s approval is as an add-on therapy in adults with active autoantibody-positive SLE with a high degree of disease activity despite standard therapy (e.g., positive anti-dsDNA and low complement). This once-weekly injection will be available in 200 mg single-dose prefilled syringes and single-dose prefilled pens (autoinjector). Belimumab is also available as an existing intravenous formulation.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

This approval is based on results of the BLISS-SC Phase 3 study, which included more than 800 patients with active SLE. BLISS-SC measured disease activity reduction at Week 52 in patients who received belimumab plus standard care compared with patients who received placebo plus standard care. This formulation was approved in the U.S. in July 2017.

Risk of Heart-Related Death with Febuxostat
On Nov. 15, the FDA alerted the public that preliminary results from a safety trial showed patients taking febuxostat (Uloric) for gout have an increased risk of heart-related death compared with those on allopurinol. When the final post-marketing trial results are received, the FDA will conduct a comprehensive review and update the public with any additional information.2 Currently, febuxostat drug labels already have a Warning and Precaution about cardiovascular events due to the higher rate of cardiac problems found during pre-marketing clinical trials.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In 2009 when febuxostat was FDA approved, its manufacturers were mandated to conduct this additional safety trial because pre-marketing clinical trials found a higher rate of cardiac problems, which include myocardial infarction (MI), stroke and heart-related death, in febuxostat-treated patients compared with allopurinol-treated patients.

The safety study was designed to gain a better understanding of febuxostat and its effects. It evaluated more than 6,000 gout patients treated with febuxostat or allopurinol. The primary outcome was a combination of heart-related death, non-fatal MI, non-fatal stroke and a condition of inadequate blood supply to the heart requiring urgent surgery.

The preliminary safety study results demonstrated that, overall, febuxostat did not increase the risk of these events compared with allopurinol. However, when the outcomes were evaluated separately, patients treated with febuxostat had an increased risk of heart-related death and death from all causes.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. GlaxoSmithKline Plc. News release: GSK receives European marketing authorization for self-injectable formulation of Benlysta for the treatment of systemic lupus erythematosus. 2017 Nov 13.
  2. U.S. Food and Drug Administration. Safety alert: Febuxostat (brand name Uloric): Drug safety communication—FDA to evaluate increased risk of heart-related death. 2017 Nov 15.

Pages: 1 2 | Multi-Page

Filed Under: Drug Updates Tagged With: belimumab, cardiovascular, European Union, Febuxostat, Gout, International, systemic lupus erythematosus (SLE)

You Might Also Like:
  • FDA Issues Boxed Warning for Febuxostat & Approves Colchicine for Gout Flare
  • Subcutaneous Belimumab Improves Systemic Lupus Srythematosus Outcomes
  • Ixekizumab Promising for Non-Radiographic Axial SpA; Plus FDA Approves Belimumab for Pediatric Lupus
  • Alendronate May Provide Cardiovascular Benefits; Plus FDA Approves Subcutaneous Tocilizumab

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.